Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Updated Clinical Studies Continue to Show Promise of OXiGENE's Drug Candidate, CA4P, for the Treatment of Advanced Ovarian Cancer
Updated Clinical Studies Continue to Show Promise of OXiGENE's Drug Candidate, CA4P, for the Treatment of Advanced Ovarian Cancer WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 15, 2005--OXiGENE, Inc. -- Principal Investigator Provides Interim Update to Clinical Trial; Data Shows Additional Responders in
View HTML
Toggle Summary Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic Drugs in the Fight against Cancer at AACR Conference
Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic Drugs in the Fight against Cancer at AACR Conference WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2005--OXiGENE, Inc.
View HTML
Toggle Summary OXiGENE To Participate in the S.G. Cowen & Company 6th Annual Global Healthcare Conference; Company Presentation to Be Available via Webcast
OXiGENE To Participate in the S.G. Cowen & Company 6th Annual Global Healthcare Conference; Company Presentation to Be Available via Webcast WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 3, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer
View HTML
Toggle Summary OXiGENE to Participate in the Rodman and Renshaw Techvest 7th Annual Healthcare Conference; Company Presentation to Be Available via Webcast
OXiGENE to Participate in the Rodman and Renshaw Techvest 7th Annual Healthcare Conference; Company Presentation to Be Available via Webcast WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 31, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer
View HTML
Toggle Summary OXiGENE Reports Third-Quarter 2005 Operational and Financial Results
OXiGENE Reports Third-Quarter 2005 Operational and Financial Results WALTHAM, Mass., Oct 26, 2005 (BUSINESS WIRE) -- Company Reports Significant Achievements for the Quarter including: -- Initiation of a Phase II Clinical Trial in Platinum-Resistant Ovarian Cancer -- Observation of an Early
View HTML
Toggle Summary OXiGENE to Participate in the MassOpps Biotech Investment Conference; Company Presentation to Be Available via Webcast
OXiGENE to Participate in the MassOpps Biotech Investment Conference; Company Presentation to Be Available via Webcast WALTHAM, Mass., Oct 21, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain
View HTML
Toggle Summary OXiGENE to Webcast Third-Quarter 2005 Financial Results Conference Call; Live Internet Webcast to be Available at www.oxigene.com
OXiGENE to Webcast Third-Quarter 2005 Financial Results Conference Call; Live Internet Webcast to be Available at www.oxigene.com WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 14, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain
View HTML
Toggle Summary MEDIA ADVISORY: Oncology Notables Gather to Discuss Tumor-Selective Medicines; OXiGene's Chief Scientific Officer Discusses Mechanism of Action and Clinical Results of Combretastatin A4P at Royal Pharmaceutical Society Meeting
MEDIA ADVISORY: Oncology Notables Gather to Discuss Tumor-Selective Medicines; OXiGene's Chief Scientific Officer Discusses Mechanism of Action and Clinical Results of Combretastatin A4P at Royal Pharmaceutical Society Meeting WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 12, 2005--OXiGENE, Inc.
View HTML
Toggle Summary New Research Highlights a Novel Mechanism of Action for OXiGENE's Lead Vascular Disrupting Agent, CA4P
New Research Highlights a Novel Mechanism of Action for OXiGENE's Lead Vascular Disrupting Agent, CA4P "CA4P Disrupts VE-Cadherin Signaling Pathway and Leads To Rapid Vascular Collapse And Tumor Necrosis," Notes Investigators In Peer-Reviewed Publication, The Journal Of Clinical Investigation --
View HTML
Toggle Summary Positive Clinical Trial Data Reported for OXiGENE's Vascular Disrupting Agent, CA4P, in Combination Trial with Radiotherapy
Positive Clinical Trial Data Reported for OXiGENE's Vascular Disrupting Agent, CA4P, in Combination Trial with Radiotherapy WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 5, 2005-- Side Effects Minimal, with No Unexpected Toxicities Beyond Radiotherapy Alone, Including at High Dose Levels of CA4P
View HTML